Evidence map›Paper›PMID 40089472›Full record

ArticleNature communications2025

Asymmetric reductive arylation and alkenylation to access S-chirogenic sulfinamides.

Xiaowu Fang, Longlong Xi, Minyan Wang, Jieshuai Xiao, Yue Zhao, Michael C Willis, Zhuangzhi Shi

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Asymmetric Synthesis ofJournal of the American Chemical Society · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaowu Fang *State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China.
Longlong Xi *State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China.ORCID http://orcid.org/0009-0009-6433-6156
Minyan WangState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China. wangmy@nju.edu.cn.ORCID http://orcid.org/0000-0003-3896-5986
Jieshuai XiaoState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China.
Yue ZhaoState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China.ORCID http://orcid.org/0000-0001-6094-4087
Michael C WillisDepartment of Chemistry, University of Oxford, Oxford, UK. michael.willis@chem.ox.ac.uk.ORCID http://orcid.org/0000-0002-0636-6471
Zhuangzhi ShiState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China. shiz@nju.edu.cn.ORCID http://orcid.org/0000-0003-4571-4413

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study of the stereochemistry of organic sulfur compounds has been ongoing for over a century, with S-chirogenic pharmacophores playing an essential role in drug discovery within bioscience and medicinal chemistry. Traditionally, the synthesis of sulfinamides featuring stereogenic sulfur(IV) centers involves a complex, multistep process that often depends on chiral auxiliaries or kinetic resolution. Here, we introduce an effective and versatile method for synthesizing diverse classes of S-chirogenic sulfinamides through selective aryl and alkenyl addition to sulfinylamines. This process is catalysed by a chiral nickel or cobalt complex under reductive conditions, and eliminating the need for preformed organometallic reagents. The method facilitates the incorporation of a diverse array of aryl and alkenyl halides at the sulfur position, enabling their integration into various biologically significant sulfur pharmacophores. Our detailed mechanistic investigations and density functional theory calculations provide insights into the reaction pathway, particularly highlighting the enantiocontrol mode during addition process.

Identifiers

PMID40089472
PMCPMC11910617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.